Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
- 31 January 2010
- journal article
- research article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 116 (1), 15-20
- https://doi.org/10.1016/j.ygyno.2009.09.025
Abstract
No abstract availableFunding Information
- Genentech (CA 27469, CA 37517)
- Genentech (CA 27469, CA 37517)
- National Cancer Institute (CA 27469, CA 37517)
This publication has 24 references indexed in Scilit:
- Mutual exclusiveness betweenPIK3CAandKRASmutations in endometrial carcinomaInternational Journal of Gynecologic Cancer, 2008
- An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group studyGynecologic Oncology, 2008
- Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN DeficiencyClinical Cancer Research, 2007
- HER-2/neuoverexpression in uterine papillary serous cancers and its possible therapeutic implicationsInternational Journal of Gynecologic Cancer, 2006
- HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged PatientsJournal of Clinical Oncology, 2006
- Use of trastuzumab in the treatment of metastatic endometrial cancerInternational Journal of Gynecologic Cancer, 2006
- High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial CarcinomaCancer Research, 2005
- Antibody-based targeted therapy for gastric cancerGastric Cancer, 2005
- Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridizationGynecologic Oncology, 2005
- Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization. Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and Ki-67 protein expression, and outcomeLaboratory Investigation, 2004